RA
VYNT

Royce & Associates’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Royce & Associates’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-116
Closed -$136K – 1186
2015
Q3 		$136K Sell
116
-263
-69% -$403K ﹤0.01% 1118
2015
Q2 		$669K Hold
379
– – ﹤0.01% 1058
2015
Q1 		$444K Hold
379
– – ﹤0.01% 1087
2014
Q4 		$380K Buy
+379
New +$380K ﹤0.01% 1158

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QGM
Quality Growth Management Rancho Santa Fe, California $88.9M AUM
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Royce & Associates's VYNT Position: Q4 2015 in Review

Royce & Associates sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2015, closing a stake of 116 shares — an estimated $136K sold.

Royce & Associates first reported a position in VYNT in Q4 2014 and held it in 4 quarters. The position peaked at $669K in Q2 2015. 40 funds tracked by Wall St. Rank hold VYNT as of Q4 2015.

  • Royce & Associates reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Royce & Associates sold 116 Vyant Bio, Inc. Common Stock shares in Q4 2015, an estimated $136K.
  • Royce & Associates first reported a position in Vyant Bio, Inc. Common Stock in Q4 2014 and held it in 4 quarters.
  • Royce & Associates's Vyant Bio, Inc. Common Stock position peaked at $669K in Q2 2015.
  • 40 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2015.

Based on Royce & Associates's 13F filing for Q4 2015, filed 9 Feb 2016.